BriaCell Shows Immunotherapy Data at SITC 2026
Four preclinical posters from BriaCell and BriaPro highlight new immunotherapy platform and checkpoint-modulating candidates at the annual meeting in Phoenix.
Updated on Nov. 6, 2026 in Biotech
BriaCell Therapeutics and BriaPro Therapeutics presented four preclinical immunotherapy posters at the SITC 41st Anniversary Annual Meeting, held November 4-8, 2026, in Phoenix, AZ. The findings cover the off-the-shelf Bria-OTS+ platform, the BP-80 CD28 co-stimulatory candidate, and the TILsRx-001 PD-L1 antagonist.
Why it matters
The data point to continued development of BriaCell's immunotherapy pipeline across multiple cancer indications. Preclinical results of this kind help determine which candidates move toward clinical testing.
TILsRx-001 bound PD-L1 with 49-fold higher affinity than the construct lacking CD80 mutations, and CD80-Fc showed 130-fold PD-L1 binding versus the wild-type CD80 sequence. These are preclinical cell-based and engineering measurements, and the human relevance of these affinity gains has not been established.
The players
BriaCell Therapeutics
BriaCell Therapeutics is a clinical-stage biotechnology company developing immunotherapies for cancer, with operations linked to Philadelphia and Vancouver.
BriaPro Therapeutics
BriaPro Therapeutics is a company that co-presented the preclinical immunotherapy posters with BriaCell at the SITC meeting.
Society for Immunotherapy of Cancer (SITC)
SITC is a professional society that organizes an annual scientific meeting focused on cancer immunotherapy research.
The details
Bria-OTS+ is an off-the-shelf cellular immunotherapy platform that broadly activated innate and adaptive immune cells, including cells from patients with breast and prostate cancer, and enhanced cancer-cell killing across multiple tumor lines. BP-80 counteracted CTLA-4-mediated inhibition in cell assays and was well tolerated with no treatment-related pathological findings in a four-week nonhuman primate study.
Timeline
November 4-8, 2026: SITC 41st Anniversary Annual Meeting in Phoenix, AZ.
November 6, 2026: Bria-OTS+ and TILsRx-001 poster presentations.
November 7, 2026: BP-80 and CD80 variant poster presentations.
Pipeline Context
The posters were presented at the SITC 41st Anniversary Annual Meeting in Phoenix, the annual forum where cancer immunotherapy researchers share checkpoint-modulator and cell-therapy findings. BriaCell's data on CD28 co-stimulation and PD-L1 antagonism places its candidates within the same checkpoint-focused research direction discussed at that meeting.
The findings are preclinical and do not yet change how patients are treated, so no immediate changes to care or access are indicated. Readers following cancer treatment options should watch for whether these candidates enter human clinical testing.
The takeaway
Preclinical checkpoint and cell-therapy data are an early stage of drug development, and readers should treat these results as signals rather than established treatments. Follow peer review and human trial registrations to judge whether the approaches hold up.
Further reading
For related coverage, see Biotech news in the United States.
More information
Copies of the posters are available on the BriaCell scientific publications page.
Source note: This article includes information reported by The Manila times.
